HER-2/neu status and response to CMF: Retrospective study in a series of operable breast cancer treated with primary CMF chemotherapy

Journal of Cancer Research and Clinical Oncology

Volumn 133, Issue 7, 2007, Pages 423-429

  Falo, Catalina ^a,b,c   Moreno, Abelardo ^a   Varela, Mar ^a,b   Lloveras, Belen ^a,b   Figueras, Agnès ^a,b   Escobedo, Agustín ^a,b  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b HOSPITAL DURAN I REYNALS   (Spain)

^c CATALAN INSTITUTE OF ONCOLOGY   (Spain)

Author keywords

Breast carcinoma; Her 2 neu; Primary chemotherapy; Response; Survival

Indexed keywords

CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE MARKER; DRUG RESPONSE; FEMALE; FOLLOW UP; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; UNIVARIATE ANALYSIS;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; GENE AMPLIFICATION; GENES, ERBB-2; HUMANS; MAMMOGRAPHY; METHOTREXATE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 34249057860     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-006-0176-7     Document Type: Article

References (27)

1. Allred DC, Clark GM, Tandon AK et al (1992) HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 10:599-605
2. Bargmann CI, Hung MC, Weinberg (1986) The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 319:226-230
3. Baselga J, Seidman AD, Rosen PP et al (1997) HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications. Oncology 11:43-48
4. Bonadonna G, Valagussa P, Brambilla C et al (1998) Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol 16:93-100
5. Buchholz TA, Huang EH, Berry D et al (2004) HER2/neu positive disease does not increase risk of locorregional recurrence for patients treated with neoadjuvant doxorrubicin-based chemotherapy, mastectomy, and radiotherapy. Int J Radiat Oncol Biol Phys 59:1337-1342
6. Falo C, Moreno A, Lloveras B et al (2003) Algorithm for the diagnosis of HER-2/neu status in breast infiltrating carcinomas. Am J Clinical Oncol 26:465-470
7. Falo C, Moreno A, Benito E et al (2005) Primary chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil in operable breast carcinoma. Cancer 12:657-663
8. Fisher B, Bryant J, Wolmark N et al (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672-2685
9. Goldhirsch A, Glick JH, Gelber RD et al (2005) Meeting Highlights: International Expert consensus on the primary therapy of early breast cancer 2005. Ann of Oncol 16:1569-1583
10. Gusterson BA, Gelber RD, Goldhirsch A et al (1992) Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 10:1049-1056
11. Haffty BG, Brown F, Carter D et al (1996) Evaluation of HER-2/neu oncoprotein expression as a prognostic indicator of local recurrence in conservatively treated breast cancer: a case-control study. Int J Radiat Oncol Biol Phys 35:751-757
12. Konecny GE, Thomssen Ch, Lück HJ et al (2004) HER-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. J Natl Cancer Inst 96:1141-1151
13. Martin M, Pienkowski T, Mackey J et al (2005) Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352:2302-2313
14. Ménard S, Valagussa P, Pilotti S et al (2001) Response to cyclophosphamide, methrotrexate and fluorouracil in lymph node-positive breast cancer according to HER-2 overexpression and other tumor biologic variables. J Clin Oncol 19:329-335
15. Miles DW, Harris WH, Gillett CE et al (1999) Effect of c-erbB(2) and estrogen receptor status on survival of women with primary breast cancer treated with adjuvant cyclophosphamide/methotrexate/fluorouracil. Int J Cancer 84:354-359
16. Moreno A, Lloveras B, Figueras A et al (1997) Ductal carcinoma in situ of the breast: correlation between histologic classifications and biologic markers. Mod Pathol 10(11):1088-1092
17. Moreno A, Escobedo A, Benito E, Serra JM, Guma A, Riu F (2002) Pathologic changes related to CMF primary chemotherapy in breast cancer. Pathological evaluation of response predicts clinical outcome. Breast Cancer Res Treat 75(2):119-125
18. Muss HB, Thor AD, Berry DA et al (1994) C-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330:1260-1266
19. Paik S, Hazan R, Fisher ER et al (1990) Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of c-erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 8:103-112
20. Paik S, Bryant J, Tan-Chiu E et al (2000) HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast And Bowel Project Protocol B-15. J Natl Cancer Inst 92:1991-1998
21. Reed W, Hannisdal E, Boehler PJ et al (2000) The prognostic value of p53 and c-erbB-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years. Cancer 88:804-813
22. Slamon DJ, Clark GM, Wong SG et al (1987) Human breast cancer. Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182
23. Sorlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869-10874
24. Van de Vijver MJ, Peterse JL, Mooi WJ et al (1988) Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 319:1239-1245
25. van't Veer LJ, Dai H, van de Vijver MJ et al (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature (Lond) 415:530-536
26. Wright C, Nicholson S, Angus B et al (1992) Relationship between c-erB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 65:118-121
27. Yang W, Klos Ks, Zhou X et al (2003) ErbB2 overexpression in human breast carcinoma is correlated with p21Cip1 up-regulation and tyrosine-15 hyperphosphorilation of p34Cdc2: poor responsiveness to chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil is associated with ErbB2 overexpression and with p21Cip1 overexpression. Cancer 98:1123-1130